Trial Profile
A Retrospective, Single Institution Study Investigating Cardiovascular Adverse Events (CvAE) Associated with Carfilzomib (Ky) in a Non-Caucasian Cohort of Patients Diagnosed with Multiple Myeloma (MM)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Jun 2018
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 24 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.